Last Updated: May 3, 2026

BUMETANIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Bumetanide, and when can generic versions of Bumetanide launch?

Bumetanide is a drug marketed by Anthea Pharma, Aspiro, Gland, Hospira, Lupin Ltd, MSN, Qilu Pharm Hainan, Sagent, Teva Parenteral, West-ward Pharms Int, Amneal Pharms Co, Appco, Heritage Pharma, Jubilant Generics, Mankind Pharma, Rising, Rubicon Research, Sandoz, Taro, Upsher Smith Labs, and Zydus Pharms. and is included in twenty-three NDAs.

The generic ingredient in BUMETANIDE is bumetanide. There are six drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the bumetanide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bumetanide

A generic version of BUMETANIDE was approved as bumetanide by SAGENT on January 27^th, 1995.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for BUMETANIDE?
What are the global sales for BUMETANIDE?
What is Average Wholesale Price for BUMETANIDE?

Summary for BUMETANIDE

US Patents:	0
Applicants:	21
NDAs:	23

US Patents and Regulatory Information for BUMETANIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro	BUMETANIDE	bumetanide	TABLET;ORAL	213458-003	Jul 24, 2023	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Rising	BUMETANIDE	bumetanide	TABLET;ORAL	212019-003	Dec 12, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Pharms	BUMETANIDE	bumetanide	TABLET;ORAL	202900-001	Apr 30, 2018	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	BUMETANIDE	bumetanide	TABLET;ORAL	215362-002	Feb 5, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Rubicon Research	BUMETANIDE	bumetanide	TABLET;ORAL	213942-001	Dec 27, 2024	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.